Your browser doesn't support javascript.
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Kaptein, Suzanne J F; Jacobs, Sofie; Langendries, Lana; Seldeslachts, Laura; Ter Horst, Sebastiaan; Liesenborghs, Laurens; Hens, Bart; Vergote, Valentijn; Heylen, Elisabeth; Barthelemy, Karine; Maas, Elke; De Keyzer, Carolien; Bervoets, Lindsey; Rymenants, Jasper; Van Buyten, Tina; Zhang, Xin; Abdelnabi, Rana; Pang, Juanita; Williams, Rachel; Thibaut, Hendrik Jan; Dallmeier, Kai; Boudewijns, Robbert; Wouters, Jens; Augustijns, Patrick; Verougstraete, Nick; Cawthorne, Christopher; Breuer, Judith; Solas, Caroline; Weynand, Birgit; Annaert, Pieter; Spriet, Isabel; Vande Velde, Greetje; Neyts, Johan; Rocha-Pereira, Joana; Delang, Leen.
  • Kaptein SJF; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; suzanne.kaptein@kuleuven.be johan.neyts@kuleuven.be joana.rochapereira@kuleuven.be leen.delang@kuleuven.be
  • Jacobs S; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Langendries L; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Seldeslachts L; Biomedical MRI and Molecular Small Animal Imaging Centre, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Ter Horst S; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Liesenborghs L; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Hens B; Drug Delivery & Disposition, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Vergote V; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Heylen E; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Barthelemy K; Unité des Virus Emergents, Aix Marseille University, Institut de Recherche pour le Développement (IRD) 190, Institut National de la Santé et de la Recherche Médicale (INSERM) 1207, 13005 Marseille, France.
  • Maas E; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • De Keyzer C; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Bervoets L; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Rymenants J; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Van Buyten T; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Zhang X; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Abdelnabi R; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Pang J; UCL Great Ormond Street Institute of Child Health, University College London, WC1N 1EH London, United Kingdom.
  • Williams R; UCL Great Ormond Street Institute of Child Health, University College London, WC1N 1EH London, United Kingdom.
  • Thibaut HJ; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Dallmeier K; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Boudewijns R; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Wouters J; Molecular Small Animal Imaging Centre, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Augustijns P; Drug Delivery & Disposition, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Verougstraete N; Department of Laboratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium.
  • Cawthorne C; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Breuer J; UCL Great Ormond Street Institute of Child Health, University College London, WC1N 1EH London, United Kingdom.
  • Solas C; Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Unité des Virus Emergents, Institut de Recherche pour le Développement (IRD) 190, Institut National de la Santé et de la Recherche Médicale (INSERM) 1207, Laboratoire de Pharmacocinétique et Toxicologie, 13005 Marseille, France.
  • Weynand B; Translational Cell and Tissue Research, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Annaert P; Drug Delivery & Disposition, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Spriet I; Pharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium.
  • Vande Velde G; Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven-University of Leuven, 3000 Leuven, Belgium.
  • Neyts J; Biomedical MRI and Molecular Small Animal Imaging Centre, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
  • Rocha-Pereira J; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; suzanne.kaptein@kuleuven.be johan.neyts@kuleuven.be joana.rochapereira@kuleuven.be leen.delang@kuleuven.be
  • Delang L; Global Virus Network, Baltimore, MD 21201.
Proc Natl Acad Sci U S A ; 117(43): 26955-26965, 2020 10 27.
Article in English | MEDLINE | ID: covidwho-841910
Semantic information from SemMedBD (by NLM)
1. favipiravir TREATS Hamsters
Subject
favipiravir
Predicate
TREATS
Object
Hamsters
2. Pharmaceutical Preparations ADMINISTERED_TO Animal Model
Subject
Pharmaceutical Preparations
Predicate
ADMINISTERED_TO
Object
Animal Model
3. hydroxychloroquine NEG_TREATS Virus
Subject
hydroxychloroquine
Predicate
NEG_TREATS
Object
Virus
4. favipiravir NEG_TREATS Virus
Subject
favipiravir
Predicate
NEG_TREATS
Object
Virus
5. Lung LOCATION_OF favipiravir
Subject
Lung
Predicate
LOCATION_OF
Object
favipiravir
6. Pharmaceutical Preparations TREATS COVID-19
Subject
Pharmaceutical Preparations
Predicate
TREATS
Object
COVID-19
7. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
8. Pharmaceutical Preparations TREATS Patients
Subject
Pharmaceutical Preparations
Predicate
TREATS
Object
Patients
9. Antiviral Agents TREATS Animal Disease Models
Subject
Antiviral Agents
Predicate
TREATS
Object
Animal Disease Models
10. favipiravir TREATS Hamsters
Subject
favipiravir
Predicate
TREATS
Object
Hamsters
11. Pharmaceutical Preparations ADMINISTERED_TO Animal Model
Subject
Pharmaceutical Preparations
Predicate
ADMINISTERED_TO
Object
Animal Model
12. hydroxychloroquine NEG_TREATS Virus
Subject
hydroxychloroquine
Predicate
NEG_TREATS
Object
Virus
13. favipiravir NEG_TREATS Virus
Subject
favipiravir
Predicate
NEG_TREATS
Object
Virus
14. Lung LOCATION_OF favipiravir
Subject
Lung
Predicate
LOCATION_OF
Object
favipiravir
15. Pharmaceutical Preparations TREATS COVID-19
Subject
Pharmaceutical Preparations
Predicate
TREATS
Object
COVID-19
16. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
17. Pharmaceutical Preparations TREATS Patients
Subject
Pharmaceutical Preparations
Predicate
TREATS
Object
Patients
18. Antiviral Agents TREATS Animal Disease Models
Subject
Antiviral Agents
Predicate
TREATS
Object
Animal Disease Models
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the globe after its emergence in Wuhan in December 2019. With no specific therapeutic and prophylactic options available, the virus has infected millions of people of which more than half a million succumbed to the viral disease, COVID-19. The urgent need for an effective treatment together with a lack of small animal infection models has led to clinical trials using repurposed drugs without preclinical evidence of their in vivo efficacy. We established an infection model in Syrian hamsters to evaluate the efficacy of small molecules on both infection and transmission. Treatment of SARS-CoV-2-infected hamsters with a low dose of favipiravir or hydroxychloroquine with(out) azithromycin resulted in, respectively, a mild or no reduction in virus levels. However, high doses of favipiravir significantly reduced infectious virus titers in the lungs and markedly improved lung histopathology. Moreover, a high dose of favipiravir decreased virus transmission by direct contact, whereas hydroxychloroquine failed as prophylaxis. Pharmacokinetic modeling of hydroxychloroquine suggested that the total lung exposure to the drug did not cause the failure. Our data on hydroxychloroquine (together with previous reports in macaques and ferrets) thus provide no scientific basis for the use of this drug in COVID-19 patients. In contrast, the results with favipiravir demonstrate that an antiviral drug at nontoxic doses exhibits a marked protective effect against SARS-CoV-2 in a small animal model. Clinical studies are required to assess whether a similar antiviral effect is achievable in humans without toxic effects.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Betacoronavirus / Amides / Hydroxychloroquine Topics: Traditional medicine Limits: Animals Language: English Journal: Proc Natl Acad Sci U S A Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Betacoronavirus / Amides / Hydroxychloroquine Topics: Traditional medicine Limits: Animals Language: English Journal: Proc Natl Acad Sci U S A Year: 2020 Document Type: Article